Cue Biopharma Cash Flow-to-Debt Ratio
Cue Biopharma cash flow-to-debt ratio. Cue Biopharma (CUE) has a Cash Flow-to-Debt Ratio of -0.49x as of September 2025, meaning its operating cash flow of $-9.02 Million could theoretically repay 0% of its total liabilities ($18.40 Million) in one year. See CUE financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Cue Biopharma (2015–2024)
Cash flow-to-debt ratio of Cue Biopharma from 2015 to 2024. Historical debt coverage capacity for Cue Biopharma across 10 annual periods. Also explore Cue Biopharma equity growth rate to track the company's year-over-year net asset growth rate.
Cue Biopharma Cash Flow-to-Debt Ratio by Year (2015–2024)
Cue Biopharma cash flow-to-debt ratio by year from 2015 to 2024. Year-by-year debt coverage analysis for Cue Biopharma. For the full cash flow conversion analysis, see Cue Biopharma cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.47x | $-36.33 Million | $14.69 Million | ▼ -51.3% |
| 2023 | -1.63x | $-39.96 Million | $24.45 Million | ▼ -0.1% |
| 2022 | -1.63x | $-41.81 Million | $25.60 Million | ▲ +24.7% |
| 2021 | -2.17x | $-38.84 Million | $17.91 Million | ▼ -37.6% |
| 2020 | -1.58x | $-32.49 Million | $20.62 Million | ▲ +12.9% |
| 2019 | -1.81x | $-30.80 Million | $17.02 Million | ▲ +22.0% |
| 2018 | -2.32x | $-26.41 Million | $11.39 Million | ▼ -1.7% |
| 2017 | -2.28x | $-12.19 Million | $5.35 Million | ▲ +57.8% |
| 2016 | -5.41x | $-5.97 Million | $1.10 Million | ▼ -22.7% |
| 2015 | -4.40x | $-1.66 Million | $376.30K | — |